drugset / Trial / NCT02259881
Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
To compare with placebo the anticoagulant activity of three dosages of BIBT 986 on parameters of coagulation, platelet activation and inflammation in a model of tissue factor triggered activation of the coagulation system; to examine the safety of BIBT 986 in this setting
Timeline
- Start
- 2002-12
- Primary completion
- 2003-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BIBT 986 BS | Unknown | 0.2 mg | Intravenous |
| Subject | BIBT 986 BS | Unknown | 0.5 mg | Intravenous |
| Subject | BIBT 986 BS | Unknown | 1 mg | Intravenous |
Indications
No indication recorded.